NAS:LUNG (USA)
Business Description
Pulmonx Corp
NAICS : 334510
SIC : 3842
700 Chesapeake Drive, Redwood, CA, USA, 94063
Description
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.27 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.51 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.52 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.5 | |||||
| 3-Year EBITDA Growth Rate | -19.4 | |||||
| 3-Year EPS without NRI Growth Rate | -9.8 | |||||
| 3-Year FCF Growth Rate | -11.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 30.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.49 | |||||
| 9-Day RSI | 66.45 | |||||
| 14-Day RSI | 65.6 | |||||
| 6-1 Month Momentum % | -43.47 | |||||
| 12-1 Month Momentum % | -58.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.43 | |||||
| Quick Ratio | 8.49 | |||||
| Cash Ratio | 7.93 | |||||
| Days Inventory | 455.04 | |||||
| Days Sales Outstanding | 48.99 | |||||
| Days Payable | 75.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.5 | |||||
| Operating Margin % | -100.97 | |||||
| Net Margin % | -103.77 | |||||
| ROE % | -27.94 | |||||
| ROA % | -23 | |||||
| ROIC % | -138.75 | |||||
| ROC (Joel Greenblatt) % | -206.68 | |||||
| ROCE % | -24.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.76 | |||||
| PB Ratio | 4.8 | |||||
| Price-to-Tangible-Book | 4.88 | |||||
| EV-to-EBIT | -13.15 | |||||
| EV-to-EBITDA | -13.49 | |||||
| EV-to-Revenue | 13.36 | |||||
| EV-to-Forward-Revenue | 11.97 | |||||
| EV-to-FCF | -14.62 | |||||
| Price-to-Net-Current-Asset-Value | 5.43 | |||||
| Price-to-Net-Cash | 6.81 | |||||
| Earnings Yield (Greenblatt) % | -7.6 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:LUNG
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51.704 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | 0 | ||
| Volatility % | 45.99 | ||
| 14-Day RSI | 65.6 | ||
| 14-Day ATR ($) | 1.526904 | ||
| 20-Day SMA ($) | 18.59 | ||
| 12-1 Month Momentum % | -58.71 | ||
| 52-Week Range ($) | 13.7926 - 45.49 | ||
| Shares Outstanding (Mil) | 37.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pulmonx Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||